The Food and Drugs Authority (FDA) has revoked the Good Manufacturing Practices (GMP) certification of Aveo Pharmaceuticals, an Indian drug manufacturer, over its alleged role in the illegal distribution of opioid-based medications to West Africa.
The move follows a BBC Africa Eye investigation, which uncovered how Aveo Pharmaceuticals, through Westfin International, reportedly exported unapproved drugs containing tapentadol and carisoprodol to Ghana, Nigeria, and Côte d’Ivoire.
These substances, classified as highly addictive opioids, pose severe health risks, including respiratory failure and death when misused.
In response to the findings, the FDA has directed Samos Pharma, a Ghana-based importer, to sever all ties with Aveo Pharmaceuticals and Westfin International.
Additionally, the regulatory body has suspended the registration process for six products from Masters Pharmaceutical Limited, which had intended to use Aveo Pharmaceuticals as a contract manufacturer.
Reaffirming its commitment to curbing opioid abuse, the FDA emphasized its ongoing enforcement measures, including seizures, fines, and legal actions against unauthorized drug distributors.
It assured the public of continued collaboration with law enforcement agencies to prevent the influx of illicit pharmaceuticals into the country.
This latest action strengthens Ghana’s regulatory measures against illicit drug trafficking and reinforces efforts to safeguard public health.